Search Results
Aug 04, 2026, 17:06 ET CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company, announced today its second quarter 2026 financial results and provided an update following the successful
More news about: Cumberland Pharmaceuticals Inc.
Jul 28, 2026, 16:05 ET CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company
More news about: Cumberland Pharmaceuticals Inc.
Jul 13, 2026, 11:20 ET /C O R R E C T I O N -- Cumberland Pharmaceuticals Inc./
NASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized
More news about: Cumberland Pharmaceuticals Inc.
Jul 01, 2026, 09:00 ET Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
NASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based
More news about: Cumberland Pharmaceuticals Inc.
Jun 26, 2026, 11:00 ET Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
NASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, today shared updated results from its Phase
More news about: Cumberland Pharmaceuticals Inc.
Jun 22, 2026, 16:10 ET RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Jun 18, 2026, 08:00 ET RedHill Biopharma Announces Up To $19.4 Million Private Placement
pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Jun 09, 2026, 07:00 ET RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
of Helicobacter pylori (H. pylori) infection in adults10, with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Jun 08, 2026, 07:00 ET RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
pylori (H. pylori) infection in adults[1], with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Jun 02, 2026, 09:05 ET Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
NASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a
More news about: Cumberland Pharmaceuticals Inc.
Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
of Helicobacter pylori (H. pylori) infection in adults10, with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
May 28, 2026, 09:05 ET CUMBERLAND PHARMACEUTICALS ANNOUNCES LAUNCH OF VIBATIV® IN CHINA
NASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China,
More news about: Cumberland Pharmaceuticals Inc.
May 05, 2026, 17:00 ET CUMBERLAND PHARMACEUTICALS REPORTS Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., May 5, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $9.1 million during
More news about: Cumberland Pharmaceuticals Inc.
Apr 30, 2026, 07:00 ET RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
of Helicobacter pylori (H. pylori) infection in adults11, with a U.S. co-commercialization agreement with Cumberland Pharmaceuticals (NASDAQ: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Apr 28, 2026, 16:05 ET CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2026 FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after
More news about: Cumberland Pharmaceuticals Inc.
Apr 27, 2026, 08:00 ET RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
Formation of Talicia Holdings Inc. (THI) and the U.S. co-commercialization partnership with Cumberland Pharmaceuticals ("Cumberland") (Nasdaq: CPIX), including Cumberland's $4 million investment for a 30% equity interest in THI planned to drive Talicia growth, and potentially additional revenue generating
More news about: RedHill Biopharma Ltd.
Apr 23, 2026, 09:00 ET Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
NASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex ("Apotex"), the largest Canadian
More news about: Cumberland Pharmaceuticals Inc.
Apr 22, 2026, 08:00 ET RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
pylori) infection in adults[9], with a recent U.S. co-commercialization agreement with Cumberland Pharmaceuticals (Nasdaq: CPIX). RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2
More news about: RedHill Biopharma Ltd.
Apr 16, 2026, 09:05 ET CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE
NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication
More news about: Cumberland Pharmaceuticals Inc.
Mar 17, 2026, 09:05 ET Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting
NASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website
More news about: Cumberland Pharmaceuticals Inc.
Mar 04, 2026, 17:46 ET H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight
(TYO: 4579), HK-inno.N (KOSDAQ: 195940), Braintree (Sebela Pharmaceuticals), RedHill BioPharma (NASDAQ: RDHL), Cumberland Pharmaceuticals (NASDAQ: CPIX), Phathom Pharmaceuticals (NASDAQ: PHAT), and othersKey
More news about: DelveInsight Business Research, LLP
Mar 03, 2026, 17:00 ET CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH
NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million
More news about: Cumberland Pharmaceuticals Inc.
Feb 25, 2026, 07:00 ET CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional
More news about: Cumberland Pharmaceuticals Inc.
Feb 25, 2026, 07:00 ET Joint U.S. Commercialization of RedHill's Talicia® Commences
operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. ("THI") and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), has started and is now being rolled out to support accelerated market penetration and expanded reach. This marks the operational launch of the joint
More news about: RedHill Biopharma Ltd.
Feb 24, 2026, 16:05 ET CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE
NASHVILLE, Tenn., Feb. 24, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its 2025 financial results and provide a company update after the market
More news about: Cumberland Pharmaceuticals Inc.